TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Travere Therapeutics Inc (TVTX) is not an immediate buy for a beginner investor with a long-term strategy. While the company has strong revenue growth and positive analyst sentiment, the lack of recent trading signals, mixed financial performance, and neutral insider and hedge fund activity suggest that waiting for further clarity or a better entry point may be prudent.
The MACD is positive and expanding, indicating a potential upward trend. RSI is neutral at 53.976, showing no overbought or oversold conditions. The stock is trading near its pivot level of 27.428, with resistance at 28.371 and support at 26.484. Moving averages are converging, suggesting indecision in the market.
Analysts maintain positive ratings, with JPMorgan, Citi, and BofA highlighting potential upside and upcoming FDA approval for Filspari.
Revenue growth of 73.41% YoY in Q4 2025 demonstrates strong top-line performance.
Net income and EPS dropped significantly YoY, indicating profitability challenges.
No recent news or significant insider/hedge fund activity to drive momentum.
Stock trend analysis suggests limited short-term upside.
In Q4 2025, revenue increased by 73.41% YoY to $129.69M, but net income dropped by -104.53% YoY to $2.73M. EPS also declined by -104.17% YoY to $0.03. Gross margin improved slightly to 98.03%, up 1.49% YoY.
Analysts are generally bullish, with price targets ranging from $38 to $48. Citi expects FDA approval for Filspari by April 13, which could act as a catalyst. JPMorgan and BofA maintain Overweight and Buy ratings, respectively, but recent price target adjustments suggest tempered expectations.
